虽然转录因子种类繁多(>1000 种),且其功能失调常与重大疾病密切相关(特别是肿瘤等),但却通常被认为“难以靶向”(undruggable)。主要原因是转录因子大多缺乏明确的配体结合位点,目前常用的细胞水平化合物筛选体系靶向性较差,以及活性调控机制不清楚等。为了应对这些挑战,本课题组围绕重大疾病相关的转录因子,首先通过蛋白结构解析直观呈现配体结合位点,基于配体与蛋白的直接相互作用筛选靶向小分子,并以共晶和质谱等多种手段揭示其作用机制,搭建起一套独特而有效的转录因子新靶标和新靶向分子发现平台。
bHLH-PAS(basic helix-loop-helix-PER-ARNT-SIM)家族转录因子是本课题组目前重点研究的潜在药物靶标。此外,在针对BCL-2和BCL-XL蛋白、IspD酶、HNF-1α蛋白等靶标的研究中,我们通过多种技术手段,如X射线晶体学、高通量筛选和分子动力学模拟等,揭示了蛋白质与环肽或小分子配体之间的相互作用机制,为后续新型药物的开发提供了关键信息。
代表论文(转录因子药物靶标)
7. Zhuang J, Shang Q, Rastinejad F*, Wu D*. Decoding Allosteric Control in Hypoxia-Inducible Factors. J Mol Biol. 2024, 436: 168352.(*共同通讯作者)
6. Song W#, Zhuang J#, Zhang N, Ren X, Xu W, Guo M, Diao X, Liu C, Jin J, Wu D*, Zhang Y*. SAR study of 1,2-benzisothiazole dioxide compounds that agonize HIF-2 stabilization and EPO production. Bioorg Med Chem. 2023, 77: 117041.(#并列第一作者;*共同通讯作者)
5. Sun X, Jing L, Li F, Zhang M, Diao X, Zhuang J, Rastinejad F, Wu D. Structures of NPAS4-ARNT and NPAS4-ARNT2 heterodimers reveal new dimerization modalities in the bHLH-PAS transcription factor family. Proc Natl Acad Sci USA. 2022, 119: e2208804119.(独立通讯作者)
4. Ren X, Diao X, Zhuang J*, Wu D*. Structural basis for the allosteric inhibition of hypoxia-inducible factor 2 by belzutifan. Mol Pharmacol. 2022, 102: 240-247.(*共同通讯作者)
3. Diao X#, Ye F#, Zhang M, Ren X, Tian X, Lu J, Sun X, Hou Z, Chen X, Li F, Zhuang J, Ding H, Peng C, Rastinejad F*, Luo C*, Wu D*. Identification of oleoylethanolamide as an endogenous ligand for HIF-3α. Nat Commun. 2022, 13: 2529.(#并列第一作者;*共同通讯作者)
2. Zhuang J, Liu Q, Wu D*, Tie L*. Current strategies and progress for targeting the "undruggable" transcription factors. Acta Pharmacol Sin. 2022, 43: 2474-2481.(*共同通讯作者)
1. Wu D*, Su X, Lu J, Li S, Hood BL, Vasile S, Potluri N, Diao X, Kim Y, Khorasanizadeh S, Rastinejad F*. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat Chem Biol. 2019, 15: 367-376.(*共同通讯作者)[获得F1000Prime推荐]
代表论文(其他药物靶标)
3. Chen X, Zhao H, Wang C, Hamed M, Shang Q, Yang Y, Diao X, Sun X, Hu W, Jiang X, Zhang Y, Hirsch A, Wu D*, Zhuang J*. Two natural compounds as potential inhibitors against the Helicobacter pylori and Acinetobacter baumannii IspD enzymes. Int J Antimicrob Agents. 2024, 63: 107160. (#并列第一作者;*共同通讯作者)
2. Li F#*, Liu J#, Liu C#, Liu Z, Peng X, Huang Y, Chen X, Sun X, Wang S, Chen W, Xiong D, Diao X, Wang S, Zhuang J, Wu C*, Wu D*. Cyclic peptides discriminate BCL-2 and its clinical mutants from BCL-XL by engaging a single-residue discrepancy. Nat Commun. 2024, 15: 1476.(*共同通讯作者)
1. Xu M, Xu HH, Lin Y, Sun X, Wang LJ, Fang ZP, Su XH, Liang XJ, Hu Y, Liu ZM, Cheng Y, Wei Y, Li J, Li L, Liu HJ, Cheng Z, Tang N, Peng C, Li T, Liu T, Qiao L, Wu D, Ding YQ, Zhou WJ. LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis. Cell. 2019, 178: 1478-1492. [获得F1000Prime推荐]